What is Integra LifeSciences's tissue reconstruction — R&D?

Integra LifeSciences (IART) reported tissue reconstruction — R&D of $7.53M in Q1 2026.

What does tissue reconstruction — R&D mean?

This reflects the investment in innovation, clinical trials, and product development specifically for the Tissue Reconstruction portfolio. It indicates the company's commitment to long-term growth and maintaining a competitive edge in regenerative therapy markets.

Integra LifeSciences IART Tissue Reconstruction — R&D

Other segment segments

Specialty Surgery

$11.85M—

Similar metrics at other companies

ENOVReconstructive — Research and development expense

$23.79M+23.3%

QDELR&D

$2.3M-14.8%

BLCOSurgical — R&D

$13M+18.2%

ABTMedical Devices — R&D

$444M+10.7%

LIVNNeuromodulation — R&D

$40.79M+59.5%

SVRAIn Process Research And Development

$11.36M+5.9%

Other financials

Income statement

See full

Revenue$391.9M+2.4%

Gross profit$217.0M+11.6%

Operating income$11.5M+174%

Net income-$4.6M+81.7%

EPS (diluted)-$0.06+81.8%

Balance sheet

See full

Cash & equivalents$236.8M-1.0%

Total debt$2.0B+3.2%

Total equity$1.0B-31.6%

Total assets$3.6B-11.7%

Cash flow

See full

Operating cash flow$9.8M+187%

CapEx$14.8M-48.7%

Free cash flow-$5.0M+87.4%

Valuation

See full

Market cap$1.38B+53.4%

Enterprise value$3.12B+21.1%

P/S0.8×+0.3×

Profitability

See full

Gross margin51.9%-1.6pp

Operating margin-29.8%-30.3pp

Net margin-30.1%—

FCF margin3.8%-6.3pp

Returns & leverage

See full

Return on equity-38.6%—

Debt / equity1.9×+0.6×

Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's tissue reconstruction — r&d.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Integra LifeSciences's tissue reconstruction — R&D?: Integra LifeSciences (IART) reported tissue reconstruction — R&D of $7.53M in Q1 2026.
What does tissue reconstruction — R&D mean?: This reflects the investment in innovation, clinical trials, and product development specifically for the Tissue Reconstruction portfolio. It indicates the company's commitment to long-term growth and maintaining a competitive edge in regenerative therapy markets.